Paroxetine-Dextromethorphan-DDGI

Modeling of published paroxetine-dextromethorphan-DDGI studies for model evaluation

Repository files

Within this repository, we distribute a PK-Sim snapshot containing simulations of all published clinical studies used to evaluate the predictive performance of the paroxetine and dextromethorphan models regarding paroxetine-dextromethorphan-DDGIs, including the respective observed data digitized from literature reports. The applied models have been published previously [1,2].

For further details and documentation please refer to [3].

Version information

OSP Version 11.0

License

The model is distributed under the GPLv2 Lincense.

Reference

[1] Rüdesheim, S.; Selzer, D.; Mürdter, T.; Igel, S.; Kerb, R.; Schwab, M.; Lehr, T. Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone. Pharmaceutics 2022, 14, 1734.

[2] Rüdesheim S, Selzer D, Fuhr U, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. CPT Pharmacometrics Syst Pharmacol. 2022;00:1- 18.

[3] Rüdesheim S, Loer HLH, Feick D, Marok FZ, Fuhr LM, Selzer D, Teutonico, D, Schneider ARP, Solodenko J, Frechen S, vdL Maaike, Moes DJAR, Swen JJ, Schwab M, Lehr T. A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development. Clin Pharmacol Ther. 2025, doi: 10.1002/cpt.3604.